We found that a lower promoter methylation of IRX3 was associated with a significantly higher all-cause but not cardiovascular mortality within two years after TAVI in both univariable and multivariable analyses, suggesting circulating methylated IRX3 DNA as a novel prognostic biomarker in patients with AS. The gene discussed is IRX3; the disease is aortic stenosis.